Dr. Martens

Dr. Martens reported EPS of 4.23p for the second half of 2026, missing analysts' estimate of 4.84p; revenue of £442.95m was slightly below expectations. At the same time, adjusted profit before tax rose 61% and the gross margin improved due to a strategic focus on full‑price sales. The stock rose 1.04% after the results, and management provided an outlook with EPS forecasts of $1.52 (2027) and $1.68 (2028). » Más en de.investing.com

Dr. Martens reported a 3.1% decline in revenue to £251 million for the third quarter of 2025/26 after offering fewer discounts. Weaker consumer demand in Europe and US tariffs are weighing on the business; in response, Dr. Martens is raising prices in the US and shifting production from Laos to Vietnam. For the full year, largely flat revenues are expected, while the stock has fallen by more than 10% after the lackluster outlook. The company also plans a broader product range with more shoes, sandals and bags to make growth profitable again. » Más en manager-magazin.de

Dr. Martens announced a multi‑year realignment aimed at higher revenue quality and a material increase in profit before tax. Despite positive signs — including regional wholesale growth for the first time in more than three years — the share fell 8.13% after the call as e‑commerce revenues were pressured by reduced promotions. Management plans price increases in the US, expansion of new product families and a cross‑channel customer focus, but sees risks from US consumer patterns and challenging EMEA conditions. » Más en de.investing.com